Addition of Pyridoxine to Prednisolone in Infantile Spasms

Status Completed

Clinical Trial Summary

Infantile spasms constitute a unique age specific epilepsy syndrome of infancy, characterized by epileptic spasms often accompanied by neurodevelopmental regression and an EEG finding of hypsarrhythmia. When all 3 components are present, the eponym "West syndrome" is commonly used. West syndrome is a catastrophic epileptic encephalopathy. It does not respond well to standard anti-epileptic drugs. Hormonal therapy is the mainstay in the treatment of infantile spasms. This includes adreno-cortico trophic hormone (ACTH) and oral steroids. Variable dose of prednisolone used in the treatment. Oral prednisolone used in usual dose (2mg/kg) has been shown to be less effective as compared to ACTH. High dose prednisolone (4mg/kg) has been used in the treatment of infantile spasms, which has been shown to be as effective as ACTH. Pyridoxine has been used as first line treatment in Japan, however there is paucity of data on the efficacy of combination of pyridoxine with hormonal therapy. There are no studies comparing add on pyridoxine with high prednisolone versus high dose prednisolone alone in the treatment of infantile spasms. Therefore the study has been planned to see whether the addition of pyridoxine with high dose prednisolone in the treatment of infantile spasms improves the efficacy in terms of spasm cessation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01828437
Study type	Interventional
Source	Lady Hardinge Medical College
Contact
Status	Completed
Phase	Phase 3
Start date	November 2012
Completion date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02299115` - Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms	Phase 3
Completed	`NCT02885389` - Molecular Genetics in Infantile Spasms	N/A
Completed	`NCT01006811` - Use of the Modified Atkins Diet in Infantile Spasms	Phase 2/Phase 3
Recruiting	`NCT01858285` - Genetics of Epilepsy and Related Disorders
Completed	`NCT00552045` - Epilepsy Phenome/Genome Project
Not yet recruiting	`NCT06315829` - Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
Completed	`NCT02220114` - Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy	N/A
Completed	`NCT02954887` - Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)	Phase 3
Completed	`NCT01723787` - Genetic Studies in Patients and Families With Infantile Spasms
Completed	`NCT02092883` - Evaluation of Neuroinflammation in Children With Infantile Spasms	Phase 4
Withdrawn	`NCT01413711` - An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms	Phase 4
Terminated	`NCT00442104` - Open-label Extension to Protocol 1042-0500	Phase 2
Completed	`NCT00441896` - A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms	Phase 2
Completed	`NCT01575639` - Prednisolone in Infantile Spasms- High Dose Versus Usual Dose	Phase 3
Withdrawn	`NCT01549288` - Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy	Phase 2/Phase 3
Completed	`NCT01073579` - Sabril Patient Registry	N/A
Completed	`NCT02953548` - Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)	Phase 3
Completed	`NCT00001325` - Metabolic Abnormalities in Children With Epilepsy	N/A
Completed	`NCT00968136` - Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study	N/A